Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Broad Center for Mendelian Genomics, |
RCV001724848 | SCV001950219 | uncertain significance | Retinitis pigmentosa | 2021-04-01 | criteria provided, single submitter | curation | The c.864+1G>C variant in BBS4 was identified in an individual with Retinitis pigmentosa, via a collaborative study between the Broad Institute's Center for Mendelian Genomics and the Pierce lab (https://oculargenomics.meei.harvard.edu/labs/pierce-lab/lab-members/). Through a review of available evidence we were able to apply the following criteria: . Based on this evidence we have classified this variant as a Variant of Uncertain Significance. If you have any questions about the classification please reach out to the Pierce Lab. |
Broad Center for Mendelian Genomics, |
RCV002227533 | SCV002507055 | uncertain significance | Bardet-Biedl syndrome 4 | 2022-05-04 | criteria provided, single submitter | curation | The heterozygous c.864+1G>C variant in BBS4 was identified by our study in the compound heterozygous state, along with another likely pathogenic variant, in 1 individual with Bardet-Biedl syndrome 4. The variant has not been previously reported in individuals with Bardet-Biedl syndrome 4 and was absent from large population studies. This variant occurs in the invariant region (+/- 1/2) of the splice consensus sequence and is predicted to cause altered splicing leading to an abnormal or absent protein. Loss of function of the BBS4 gene is a moderately established disease mechanism in autosomal recessive Bardet-Biedl syndrome 4. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2, PVS1_supporting, PM3 (Richards 2015). |
Baylor Genetics | RCV002227533 | SCV004214103 | likely pathogenic | Bardet-Biedl syndrome 4 | 2023-03-20 | criteria provided, single submitter | clinical testing |